Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395797 · ClinicalTrials.gov registry record · Phase 1
Pioglitazone for Heroin and for Nicotine Dependence
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT01395797 is a Phase 1 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 82 participants.
The verdict
NCT01395797, a Phase 1 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy. Specifically, pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be used as an adjunct to agonist-based treatment.
Interventions
- DRUG Placebo
- DRUG PIO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395797
The ClinicalTrials.gov registry entry for NCT01395797 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01395797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01395797 about?
NCT01395797 is a clinical study titled "Pioglitazone for Heroin and for Nicotine Dependence". The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy. Specifically, pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be used as an adjunct to agonist-ba...
What is the current status of trial NCT01395797?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2011-03. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01395797?
The interventions under investigation include: Placebo (DRUG), PIO (DRUG).
Who is sponsoring clinical trial NCT01395797?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.